AbbVie Inc.
ABBVNYSEPharmaceutical PreparationsFiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 3, 2026Score 10/3094% above fair value
$288.84−6.05 (-2.05%)
Close on Nov 2, 2026Market cap $510.41BP/E 81.6Yield 2.30%
AbbVie Immunology Portfolio by Quarter
Immunology Portfolio — Worldwide operational (constant-currency) growth YoY (%) (%)
AbbVie Immunology Portfolio: 14.6% in Q2 2026, up 5.4 pts from a year earlier.
Latest, Q2 2026
14.6%
Period ended Jun 30, 2026
Change on a year earlier
+5.4 pts
9.2% in Q2 2025
History
32 quarters
Since Q3 2018
Sources
32
Documents cited below
Where the Q2 2026 figure comes from
“|| Immunology | 6,957 | 1,829 | 8,786 | 14.1 | 19.2 | 15.1 | 16.8 | 14.6”
Source: Form 8-K (abbv-20260630xexhibit991.htm, filed 2026-07-31) ↗
Reported in Form 8-K Key Product Revenues Schedule.
Quarterly history
Hover a value to see the sentence it was read from; calculated values show their formula
Cite this data
StockData. (2026). AbbVie Immunology Portfolio (%), quarterly Q3 2018–Q2 2026 [Data set]. Compiled from AbbVie SEC filings and investor materials. https://stockdatahq.com/stocks/abbv/kpis/ta-imm-ww-op-yoy
See every metric in the AbbVie KPI table. Data updated Oct 26, 2026.